Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy.
about
The Gynecologist Has a Unique Role in Providing Oncofertility Care to Young Cancer PatientsFemale reproductive health after childhood, adolescent, and young adult cancers: guidelines for the assessment and management of female reproductive complicationsPretreatment antimüllerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapySerum AMH level as a marker of acute and long-term effects of chemotherapy on the ovarian follicular content: a systematic reviewImpact of breast cancer on anti-mullerian hormone levels in young womenSelf-collected dried blood spots as a tool for measuring ovarian reserve in young female cancer survivorsChanges in ovarian function in premenopausal women with breast cancer undergoing adjuvant TC (docetaxel and cyclophosphamide) chemotherapy during a brief period of amenorrhea around the last chemotherapy cycle.A highly-sensitive anti-Müllerian hormone assay improves analysis of ovarian function following chemotherapy for early breast cancer.Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patientsA comparison of disrupted sleep patterns in women with cancer-related fatigue and postmenopausal women without cancer.Fertility preservation and breast cancer: a reviewEffect of neoadjuvant chemotherapy on the serum levels of bone turnover markers in women with early-stage breast cancerOpportunities for public health communication, intervention, and future research on breast cancer in younger women.Ovarian Function, Not Age, Predicts the Benefit from Ovarian Suppression or Ablation for Premenopausal Women with Breast Cancer.Chemotherapy: Impact on Anti-Müllerian Hormone Levels in Breast Carcinoma.Prediction of ovarian function in premenopausal breast cancer patients with amenorrhoea after chemotherapy: a simple clinical scorePretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer.Prediction of postchemotherapy ovarian function using markers of ovarian reserve.Impact of tamoxifen therapy on fertility in breast cancer survivors.Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial.Genetic variants of age at menopause are not related to timing of ovarian failure in breast cancer survivors.Ovarian function after chemotherapy in young breast cancer survivors.Anti-Müllerian hormone as a marker of ovarian reserve: What have we learned, and what should we know?Assessment of ovarian function after chemotherapy in women with early and locally advanced breast cancer from Serbia.Impact of cancer treatment on risk of infertility and diminished ovarian reserve in women with polycystic ovary syndrome.Pregnancy despite ovarian insufficiency in a patient with breast cancer.Post-chemotherapy serum anti-Müllerian hormone level predicts ovarian function recovery
P2860
Q24596913-6F62F814-DF99-4DE1-8F85-B368440B5349Q28383280-0378EF69-9258-48F3-8AF9-54079A7EDE80Q28383325-C79D246F-21BF-4B92-8980-57CE00A0DA1BQ28384104-9EE2CE0D-01CA-4BD0-A9C8-BAAF9BE7E47FQ28392860-DFE6FD3D-1CD7-4594-A9CB-1E5D463B966AQ28396648-B8BC2381-6977-47BB-89DF-83E470102CD7Q33955356-44029B37-5429-416A-B4C5-6E485BB12168Q34199333-35FFCF74-1229-4B43-AEEF-76D712D3B152Q34550633-9DAA3183-C74B-4BF7-A3C6-BDBAA4C79F19Q35050788-A56F5F3E-B9C6-464D-B489-B99D769FD085Q35106163-B1A5F296-FC67-4F88-9398-297E22EDB496Q35553550-86D94688-35EF-4B25-BB00-20ECE585B77AQ35800077-3DA6E2B6-CA9E-41BA-B01E-95C754384FA7Q35920776-C60918D4-6DEC-4FCA-947C-CB34A818AA4AQ36708416-DA058CD6-0254-425F-ABCF-071C32FF8503Q37083638-7D57C98D-9E80-4031-B14C-17A71CE642A1Q37253591-10EA43A1-B130-4C56-97D6-7E780BB3542CQ37519037-73790C05-261C-426E-91D9-4ED250ECB640Q39153617-FBF796DB-A299-4F1A-BF03-43247BDA21E4Q41594757-EC14B229-D5A3-481B-B486-D6B5694B0514Q46104269-1C9F36A0-F4C1-47EF-8B17-B66820F3D0D1Q47124589-32148375-2926-4861-8D04-34BFAD83D128Q47170320-4C843C69-74B1-4BE4-9819-6FFD4B1558F6Q48365999-1F502BBB-4921-4F2B-82C1-E9F01B88A153Q50049546-72620F9F-7076-4060-8BB5-A268E86124B3Q55252088-57A8194F-029D-4A55-9B6A-042A3059AE87Q57301014-D9F923B5-FD75-4711-B210-3E721C6CD25A
P2860
Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Changes in markers of ovarian ...... ergoing adjuvant chemotherapy.
@ast
Changes in markers of ovarian ...... ergoing adjuvant chemotherapy.
@en
type
label
Changes in markers of ovarian ...... ergoing adjuvant chemotherapy.
@ast
Changes in markers of ovarian ...... ergoing adjuvant chemotherapy.
@en
prefLabel
Changes in markers of ovarian ...... ergoing adjuvant chemotherapy.
@ast
Changes in markers of ovarian ...... ergoing adjuvant chemotherapy.
@en
P2093
P2860
P356
P1433
P1476
Changes in markers of ovarian ...... ergoing adjuvant chemotherapy.
@en
P2093
Gary S Nakhuda
Katherine Crew
Michel J Ferin
Nataki Douglas
Rogerio A Lobo
P2860
P304
P356
10.1002/CNCR.25037
P407
P577
2010-05-01T00:00:00Z